Terumo (MEX:4543N) EBIT: MXN22,137 Mil (TTM As of Mar. 2026)


MEX:4543N Terumo Corp MEX:4543N
91 GF Score
Price MXN261.28
GF Value MXN373.91
Valuation Significantly Undervalued
View Full Analysis

What is Terumo EBIT?

Terumo MEX:4543N 91 EBIT is MXN22,137 Mil as of Mar. 2026. GuruFocus rates MEX:4543N with a GF Score™ of 91/100 and a GF Value™ of MXN373.91 (Significantly Undervalued).

Terumo's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN3,772 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN22,137 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Terumo's annualized ROC % for the quarter that ended in Mar. 2026 was 5.46%. Terumo's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 15.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Terumo's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.14%.


Terumo  (MEX:4543N) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Terumo's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=14297.728 * ( 1 - 16.73% )/( (219294.332 + 216474.857)/ 2 )
=11905.7181056/217884.5945
=5.46 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=260640.288 - 13847.58 - ( 27498.376 - max(0, 62326.872 - 94183.617+27498.376))
=219294.332

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=262762.242 - 14385.231 - ( 31902.154 - max(0, 61448.664 - 97848.575+31902.154))
=216474.857

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Terumo's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=15087.752/( ( (57077.428 + max(38984.307, 0)) + (57556.494 + max(36303.998, 0)) )/ 2 )
=15087.752/( ( 96061.735 + 93860.492 )/ 2 )
=15087.752/94961.1135
=15.89 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24656.082 + 38977.493 + 3051.666) - (13847.58 + 0 + 13853.354)
=38984.307

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24424.302 + 38141.443 + 3380.676) - (14385.231 + 0 + 15257.192)
=36303.998

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Terumo's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=22136.706/360807.272
=6.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Terumo EBIT Related Terms


Terumo EBIT Historical Data

* Premium members only.

The historical data trend for Terumo's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Terumo EBIT Chart

Terumo Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19,723.71 16,202.96 15,907.83 22,072.73 20,629.98

Terumo Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,454.45 7,367.95 5,703.26 5,293.56 3,771.94

MEX:4543N vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Terumo's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terumo EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Terumo's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Terumo's EV-to-EBIT falls into.


MEX:4543N
91GF Score
Terumo Corp MEX:4543N
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Terumo EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN22,137 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN22,137 Mil mean?
Terumo (MEX:4543N) has a EBIT of MXN22,137 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Terumo.
Is Terumo's EBIT too high?
Terumo's current EBIT is MXN22,137 Mil. Overall, Terumo has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terumo's EBIT compare to ISRG and BDX?
Terumo's EBIT of MXN22,137 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Terumo. Terumo's current EBIT is MXN22,137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terumo stock overvalued right now?
Based on GuruFocus' analysis, Terumo (MEX:4543N) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN373.91, compared to a current price of MXN261.28 — trading 30.1% below its estimated fair value. The current EBIT is MXN22,137 Mil. Terumo's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Terumo (MEX:4543N), the current EBIT is MXN22,137 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Terumo (MEX:4543N) Overvalued in 2026?

Based on GuruFocus' analysis, Terumo stock appears to be undervalued. The current stock price of MXN261.28 is trading 30.1% below its estimated GF Value™ of MXN373.91. GuruFocus considers Terumo to be Significantly Undervalued.

Key valuation signals for MEX:4543N:

  • EBIT: MXN22,137 Mil
  • GF Value™: MXN373.91 vs. price of MXN261.28 (30.1% below fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the MEX:4543N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Terumo Business Description

Address 2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.
91GF Score

Get the complete analysis for MEX:4543N

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN261.28
Price
MXN373.91
GF Value